TIL Technology

Publication and Scientific Presentations

2018

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma
PDF Poster | ASCO ANNUAL MEETING, JUNE 1-5, 2018 | CHICAGO, IL, USA
Abstract TPS9595 and poster number 422a – poster presented Monday, June 4th
Amod Sarnaik1, Brendan Curti2, Diwakar Davar3, John M. Kirkwood3, Omid Hamid4, Jose Lutzky5, Melissa Wilson6, Harriet Kluger7, Eric Whitman8 , Giao Phan9, Sajeve Samuel Thomas10,Karl Lewis11, Hendrik-Tobias Arkenau12, Bente Larsen13, Igor Gorbatchevsky13, Corina Andresen13,  Sam Suzuki13, Nancy Samberg13, Maria Fardis13, Jason Chesney14 1Moffitt Cancer Center, Tampa, FL; 2Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR; 3University of Pittsburgh Medical Center – Hillman Cancer Center, Pittsburgh, PA; 4The Angeles Clinic and Research Institute, Los Angeles, CA; 5Mount Sinai Comprehensive Cancer Center, Miami Beach, FL; 6New York University – Perlmutter Cancer Center – Langone Medical Center, New York, NY; 7Yale Cancer Center, New Haven, CT; 8 Atlantic Health System Cancer Care, Morristown, NJ; 9Virginia Commonwealth University, Richmond, VA; 10University of Florida Health Cancer Center, Orlando, FL; 11University of Colorado Cancer Center, Denver CO; 12Sarah Cannon Research Institute London UK; 13Iovance Biotherapeutics, San Carlos, CA; 14James Graham Brown Cancer Center, Louisville, KY

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
PDF Poster | ASCO ANNUAL MEETING, JUNE 1-5, 2018 | CHICAGO, IL, USA
Abstract TPS6096 and poster number 81a – poster presented Saturday, June 2nd 
Rom Leidner1, Ammar Sukari2, Christine Chung3, James Ohr4, Missak Haigentz5, Ezra E. W. Cohen6, Robert J. Brown7, Igor Gorbatchevsky7, Sam Suzuki7, Maria Fardis7, Robert L. Ferris4 1Earle A. Chiles Research Institute – Providence Cancer Center, Portland, OR;  2Barbara Ann Karmanos Cancer Institute, Detroit, MI;  3Moffitt Cancer Center, Tampa, FL;  4University of Pittsburgh Medical Center, Pittsburgh, PA; 5Morristown Medical Center/Atlantic Health System, Morristown, NJ; 6University of California, San Diego, CA; 7Iovance Biotherapeutics, San Carlos, CA

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma 
PDF Poster | ASCO ANNUAL MEETING, JUNE 1-5, 2018 | CHICAGO, IL, USA
Abstract TPS5604 and poster number 329a – poster presented on Monday, June 4th
Amir Jazaeri1, Robert Edwards2, Robert Wenham3, Koji Matsuo4, Gini F. Fleming5, David M. O’Malley6, Brian Slomovitz7, Bradley Monk8, Robert J. Brown9, Igor Gorbatchevsky9, Sam Suzuki9, Maria Fardis9, Emese Zsiros10  1MD Anderson Cancer Center, Houston, TX; 2University of Pittsburgh Medical Center – Hillman Cancer Center, Pittsburgh, PA; 3Moffitt Cancer Center, Tampa, FL; 4Norris Cancer Center, University of Southern California, Los Angeles, CA; 5University of Chicago, Chicago, IL; 6The James Cancer Center, Ohio State University, Columbus, OH; 7Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; 8Arizona Oncology, University of Arizona College of Medicine, and Phoenix Creighton University School of medicine at St. Joseph’s Hospital, Phoenix, AZ;  9Iovance Biotherapeutics, San Carlos, CA; 10Roswell Park Cancer Institute, Pittsburgh, PA

Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combination with Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
PDF Poster | ASCO ANNUAL MEETING, JUNE 1-5, 2018 | CHICAGO, IL, USA
Abstract TPS3107 and poster number 318a – poster presented on Monday, June 4th
Sylvia Lee1, Liza Villaruz2, Susie Tanamly3, Igor Gorbatchevsky3, Corina Andresen3,  Sam Suzuki3, Maria Fardis3, Missak Haigentz4   1University of Washington, Seattle, WA; 2University of Pittsburgh Medical Center – Hillman Cancer Center, Pittsburgh, PA; 3Iovance Biotherapeutics, San Carlos, CA; 4Atlantic Health System/Morristown Medical Center, Morristown, NJ

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO, IL, USA
Amod Sarnaik1, Brendan Curti2, Diwakar Davar3, Omid Hamid4, Jose Lutzky5, Melissa Wilson6, Harriet Kluger7, Jason Chesney8, Kevin Kim9, Giao Phan10, Sajeve Thomas11, Igor Gorbatchevsky12, Bente Larsen12, Sam Suzuki12, Nancy Samberg12, Maria Fardis12, John M. Kirkwood3

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO, IL, USA
Rom Leidner1, Ammar Sukari2, Christine Chung3, James Ohr4, Missak Haigentz5, Ezra E. W. Cohen6, Robert J. Brown7, Igor Gorbatchevsky7, Sam Suzuki7, Maria Fardis7, Robert L. Ferris4

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO, IL, USA
Amir Jazaeri1, Robert Edwards2, Robert Wenham3, Koji Matsuo4, Gini F. Fleming5, David M. O’Malley6, Brian Slomovitz7, Bradley Monk8, Robert J. Brown9, Igor Gorbatchevsky9, Sam Suzuki9, Maria Fardis9, Emese Zsiros10

Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combination with Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO, IL, USA
Sylvia Lee1, Liza Villaruz2, Susie Tanamly3, Igor Gorbatchevsky3, Sam Suzuki3, Maria Fardis3, Missak Haigentz4

Anti-OX40 Agonistic Antibody Enhances ex vivo CD8+ TIL Expansion with Increased T-cell Effector Function
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO, IL, USA
Krit Ritthipichai, Marcus Machin, Maria Fardis, and Cecile Chartier


2017

Novel Cryopreserved Tumor Infiltrating Lymphocytes (LN-144) Administered to Patients with Metastatic Melanoma Demonstrates Efficacy and Tolerability in a Multicenter Phase 2 Clinical Trial
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD, USA
Amod Sarnaik1, Jason Chesney2, Harriet Kluger3, Brendan Curti4, Omid Hamid5, Jose Lutzky6, Maria Fardis7, Igor Gorbatchevsky7, Sam Suzuki7, Bente Larsen7, Nancy L. Samberg7, John Kirkwood8

A Cryopreserved Tumor Infiltrating Lymphocyte (TIL) Product for LN-144, Generated with an Abbreviated Method Suitable for High Throughput Commercial Manufacturing Exhibits Favorable Quality Attributes For Adoptive Cell Transfer
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD, USA
Seth Wardell, Ian Frank, Lavakumar Karyampudi, Anand Veerapathran, Michelle Simpson-Abelson, Maritza Lienlaf Moreno, Michelle Blaskovich, Joseph Wypych, and Maria Fardis

Studies of Key Quality Attributes for TIL Product, LN-144
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD, USA
Krit Ritthipichai, Ian Frank, Marcus Machin, Michelle Blaskovich, Amanda Stramer, Michelle Simpson-Abelson, Maria Fardis, Cecile Chartier

A phase 2 study to evaluate the safety and efficacy of using of using autologous tumor infiltrating lymphocytes (LN -145) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD, USA
Leidner R1, Ohr J2, Chung C3, Brown RJ4, Suzuki S4, Gorbatchevsky I4, Fardis M4, and Ferris RL2

A phase 2, multicenter study to evaluate the efficacy and safety of using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD, USA
Amir Jazaeri1, Robert Edwards2, Emese Zsiros3, Robert Brown4, Igor Gorbatchevsky4, Sam Suzuki4, Maria Fardis4, Robert Wenham5

The T-cell Growth Factor Cocktail IL-2/IL-15/IL-21 Enhances Expansion and Effector Function of Tumor-Infiltrating T cells in a Novel Process Developed by Iovance
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD, USA
Michelle R. Simpson-Abelson, Christopher Mosychuk, Ian Frank, Krit Ritthipichai, and Cecile Chartier

Phenotypic and Functional Characterization of Tumor Infiltrating Lymphocytes (TIL) Grown from Non-Hodgkin Lymphoma Tumors – Implications for the Development of Novel Therapies for Lymphoma
PDF Poster | ESMO Annual Meeting, September 7-12, 2017 | Madrid, Spain
Lavakumar Karyampudi, Aishwarya Gokuladass, Michelle Blaskovich, Maria Fardis, Michael T Lotze

TIL Candidate Shows Potential in Metastatic Melanoma Based on Interim Data
News Feature | Drug Discovery & Development, 06/23/2017

Efficacy of Single Administration of Tumor Infiltrating Lymphocytes (TIL) in Heavily Pre-Treated Metastatic Melanoma Patients Following Checkpoint Therapy
PDF Poster | ASCO Annual Meeting 2017
Amod Sarnaik, Harriet Kluger, Jason Chesney, Jyothi Sethuraman, Michael T. Lotze, Bente Larsen, Igor Gorbatchevsky, Nancy L. Samberg, Sam Suzuki, Lei Wang, Mariam Mirgoli, Maria Fardis, Brendan Curti

K+ Channel Activation Promotes Tumor Infiltrating Lymphocyte (TIL) Expansion and Enhances Expression of CCR7
PDF Poster | AAI Annual Meeting 2017
Krit Ritthipichai, Marcus Machin, Michelle Simpson-Abelson, Christopher Mosychuk, Anand Veerapathran, and Michael T. Lotze

Emigrant Tumor Infiltrating Lymphocytes Profoundly Differ from Remnant T cells
PDF Poster | AACR Annual Meeting 2017
Michelle R. Simpson-Abelson, Christopher Mosychuk, Maria Fardis, and Michael T. Lotze


2016

P14 Bioluminescent redirected lysis assay (BRLA) as an efficient potency assay to assess tumor-infiltrating lymphocytes (TILs) for immunotherapy
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Aishwarya Gokuldass, Michelle A Blaskovich, Charlene Kopits, Brian Rabinovich, Michael T. Lotze

P11 Stable tumor-infiltrating lymphocytes (TIL) phenotype following cryopreservation
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Ian Frank, Amanda Stramer, Michelle A Blaskovich, Seth Wardell, Maria Fardis, James Bender, Michael T Lotze

P41 Successful expansion and characterization of tumor infiltrating lymphocytes (TILs) from non-melanoma tumors
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Jyothi Sethuraman, Laurelis Santiago, Jie Qing Chen, Zhimin Dai, Seth Wardell, James Bender, Michael T Lotze

P46 Artificial antigen presenting cells promote expansion of tumor infiltrating lymphocytes (TILs)
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Anandaraman Veerapathran, Aishwarya Gokuldass, Amanda Stramer, Jyothi Sethuraman, Michelle A Blaskovich, Doris Wiener, Ian Frank, Laurelis Santiago, Brian Rabinovich, Maria Fardis, James Bender, Michael T Lotze

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
PubMed | Journal of Clinical Oncology 2016 34:20, 2389-2397, doi: 10.1200/JCO.2016.66.7220
Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong MLM, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, and Rosenberg SA


2015

Adoptive cell transfer as personalized immunotherapy for human cancer
Science | Science 03 Apr 2015, Vol. 348, Issue 6230, pp. 62-68, DOI 10.1126/science.aaa4967
Rosenberg SA, and Restifo NP

Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.
PubMed | Clin Cancer Res. 2015;21(3):611-21
Chacon JA, Sarnaik AA, Chen JQ, et al.


2014

Finding suitable targets is the major obstacle to cancer gene therapy
Nature | Cancer Gene Ther. 2014;21(2):45-7
Rosenberg SA

Exploiting the curative potential of adoptive T-cell therapy for cancer
PubMed | Immunol Rev. 2014;257(1):56-71
Hinrichs CS, Rosenberg SA